Skip to main content
Premium Trial:

Request an Annual Quote

Craig Venter, David Galas, Jeffrey Van Ness, Marvin Selter, Richard Wennekamp, Raymond Carnahan, Herbert McDade

Premium

Craig Venter has been named to Ionian Technologies’ board of directors, the company said last week.

Venter, the former founder of Celera Genomics, currently heads three non-profits that he founded: The Center for the Advancement of Genomics; the Institute for Biological Energy Alternatives; and the Craig Venter Science Foundation. He is also founder and chairman of The Institute for Genomic Research, based in Rockville, Md.

Ionian Technologies, which is privately held and located in Upland, Calif., develops molecular diagnostics tools using isothermal DNA and RNA amplification. It was founded by David Galas and Jeffrey Van Ness as a spin-off of the Keck Graduate Institute of Applied Life Sciences in Claremont, Calif.


CytRx has named as directors Marvin Selter and Richard Wennekamp. The two replace Raymond Carnahan and Herbert McDade, who last week retired as directors. CytRx’s board remains at seven members.

Selter, who is currently president of national management-consulting firm CMS, serves on the boards of the UCLA Medical Center, San Fernando Economic Alliance, Valley Economic Development Center, and the California State University-Northridge Economic Development Center. He is also a member of the California Small Business Board, the California Budget Advisory Task Force, the City of Los Angeles Business Tax Advisory Committee, and the City of Los Angeles/Office of Finance Board of Review.

Wennekamp, meantime, is senior vice president-credit administration at Community Bank, in Pasadena, Calif. He was also special assistant to former President Gerald Ford, according to CytRx.

 

Filed under

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.